Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.91 million versus the consensus estimate of $7.05 million.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
- PepsiCo (PEP) Tops Q3 EPS by 4c, cuts EPS forecast
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
